Jorge Duconge to Methylenetetrahydrofolate Reductase (NADPH2)
This is a "connection" page, showing publications Jorge Duconge has written about Methylenetetrahydrofolate Reductase (NADPH2).
Connection Strength
0.922
-
Jim?nez-Ram?rez FJ, Castro LM, Ortiz C, Concepci?n J, Renta JY, Morales-Borges RH, Miranda-Massari JR, Duconge J. Role of treatment-modifying MTHFR677C>T and 1298A>C polymorphisms in metformin-treated Puerto Rican patients with type-2 diabetes mellitus and peripheral neuropathy. Drug Metab Pers Ther. 2017 03 01; 32(1):23-32.
Score: 0.606
-
Graydon JS, Claudio K, Baker S, Kocherla M, Ferreira M, Roche-Lima A, Rodr?guez-Maldonado J, Duconge J, Rua?o G. Ethnogeographic prevalence and implications of the 677C>T and 1298A>C MTHFR polymorphisms in US primary care populations. Biomark Med. 2019 06; 13(8):649-661.
Score: 0.177
-
Claudio-Campos K, Orengo-Mercado C, Renta JY, Peguero M, Garc?a R, Hern?ndez G, Corey S, Cadilla CL, Duconge J. Pharmacogenetics of healthy volunteers in Puerto Rico. Drug Metab Pers Ther. 2015 Dec; 30(4):239-49.
Score: 0.139